Anastrozole Tablet
Product Images NDC 68071-1682

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 68071-1682). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 1682 3

Anastrozole 1 mg tablets bottle label from NuCare Pharmaceuticals, Inc. The label indicates a quantity of 30 tablets with NDC 68071-1682-3. It includes manufacturer information, storage instructions at 68-77°F, and cautions to keep out of reach of children. Additional details include batch number, expiration, and a barcode.*

FDA Label Image

Figure 1 (Anastrozole Fig1)

A Kaplan-Meier survival curve showing disease-free survival in months for patients treated with anastrozole versus tamoxifen. The x-axis represents time in months up to 96, and the y-axis shows the proportion alive and disease-free ranging from 0.0 to 1.0. Two curves compare the randomized treatments, with number of patients at risk listed below the graph for each treatment group at various time points.*

FDA Label Image

Figure 2 (Anastrozole Fig2)

A Kaplan-Meier survival curve showing disease-free survival over 96 months comparing two randomized treatments: anastrozole (dashed line) and tamoxifen (solid line). The y-axis represents the proportion of patients alive and disease-free, while the x-axis represents months of follow-up. Below the graph, the number of patients at risk for each treatment arm is displayed at various time points.*

FDA Label Image

Figure 3 (Anastrozole Fig3)

A Kaplan-Meier survival curve chart comparing recurrence-free proportions over time in months for two treatments: Anastrozole (solid line) and Tamoxifen (dashed line). The x-axis represents time to event up to 120 months, and the y-axis shows the proportion recurrence-free, ranging from 0.5 to 1.0. The number of patients at risk is listed below the x-axis at various time points for each treatment group. The vertical axis is truncated for clarity of the curves.*

FDA Label Image

Figure 4 (Anastrozole Fig4)

A Kaplan-Meier survival curve chart comparing the proportion of patients over time (months) between two randomized treatments: Anastrozole and Tamoxifen. The y-axis represents the proportion event-free, with values descending from 1.00 to about 0.55. The x-axis represents time to event in months, ranging from 0 to 120 months. Below the graph, the number of patients at risk at various time points is shown for both treatment groups. A note mentions that the proportion of patients with 120 months' follow-up was 29.8%.*

FDA Label Image

Figure 5 (Anastrozole Fig5)

A Kaplan-Meier curve displaying time to progression in months comparing Anastrozole and Tamoxifen treatments. The y-axis shows the proportion of patients not progressing, while the x-axis represents months. Two lines distinguish randomized treatment groups for Anastrozole and Tamoxifen, with accompanying patient risk numbers below the graph.*

FDA Label Image

Figure 6 (Anastrozole Fig6)

A Kaplan-Meier survival curve chart comparing the proportion of patients not progressed over time (in months) between two randomized treatments: Anastrozole and Tamoxifen. The x-axis represents time to progression in months and the y-axis shows the proportion not progressed, ranging from 0 to 1. Below the x-axis is a table listing patient numbers at risk at various time points for each treatment group.*

FDA Label Image

Chemical Structure For Anastrozole (Anastrozole Str)

Chemical structure of anastrozole depicted as a molecular diagram showing the arrangement of atoms and bonds characteristic of this nonsteroidal aromatase inhibitor.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.